Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to
improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof
have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat
diseases and make a sustainable contribution to society. The company also aims for improving
patient access to medical innovations by working with all relevant stakeholders. Twenty-nine
medicines developed by Roche are included in the World Health Organization Model Lists of
Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.
Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals,
Biotechnology; Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016
employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D
and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member
of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information: http://www.roche.com or http://roche.jobs.